442TiPA phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignancies. (23rd October 2018) - Blagden, S; Spiliopoulou, P; Spiers, L; Gnanaranjan, C; Qi, C; Woodcock, V K; Moschandreas, J; Tyrrell, H E J; Griffiths, L; Butcher, C; Ghazaly, E; Evans, T R J